Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Dharti H. Modh, Siddharth J. Modi, Hemant Deokar, Savita Yadav & Vithal M. Kulkarni. (2023) Fibroblast growth factor receptor (FGFR) inhibitors as anticancer agents: 3D-QSAR, molecular docking and dynamics simulation studies of 1, 6-naphthyridines and pyridopyrimidines. Journal of Biomolecular Structure and Dynamics 41:8, pages 3591-3606.
Read now
Read now
Stacey J Coleman, Richard P Grose & Hemant M Kocher. (2014) Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma 1, pages 43-54.
Read now
Read now
Chen-Sheng Li, Shu-Xiang Zhang, Hong-Jun Liu, Yu-Long Shi, Le-Ping Li, Xiao-Bo Guo & Zhen-Hai Zhang. (2014) Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer. Biomarkers 19:1, pages 81-85.
Read now
Read now
Peter Traxler. (2003) Tyrosine kinases as targets in cancer therapy – successes and failures. Expert Opinion on Therapeutic Targets 7:2, pages 215-234.
Read now
Read now
Articles from other publishers (45)
Nikki Phanhthilath, Sara Hakim, Catherine Su, Andrea Liu, Divya Subramonian, Jacqueline Lesperance & Peter E. Zage. (2020) Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models. Investigational New Drugs 38:6, pages 1677-1686.
Crossref
Crossref
Farshad Abedi, Bibi Marjan Razavi & Hossein Hosseinzadeh. (2019) A review on gentisic acid as a plant derived phenolic acid and metabolite of aspirin: Comprehensive pharmacology, toxicology, and some pharmaceutical aspects. Phytotherapy Research 34:4, pages 729-741.
Crossref
Crossref
Dong-Wei Wang, Hai-Zheng Zheng, Na Cha, Xiao-Jie Zhang, Min Zheng, Ming-Ming Chen & Li-Xiang Tian. (2020) Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma. Technology in Cancer Research & Treatment 19, pages 153303382095700.
Crossref
Crossref
Yingnan Cui, Li Zhang, Jin Xing & Zhaoying Yang. (2019) Research on Mechanism of FGFR1 Inhibitor BAY1163877 against Proliferation of Breast Cancer Cells. IOP Conference Series: Materials Science and Engineering 562:1, pages 012128.
Crossref
Crossref
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty & Jose Baselga. (2019)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
FGFR
Gene Alterations
. Clinical Cancer Research 25:9, pages 2699-2707.
Crossref
Crossref
Di Lu, Junxiong Wang, Xiaoyan Shi, Bing Yue & Jianyu Hao. (2017) AHNAK2 is a potential prognostic biomarker in patients with PDAC. Oncotarget 8:19, pages 31775-31784.
Crossref
Crossref
V.C. Amann, E. Ramelyte, S. Thurneysen, R. Pitocco, N. Bentele-Jaberg, S.M. Goldinger, R. Dummer & J. Mangana. (2017) Developments in targeted therapy in melanoma. European Journal of Surgical Oncology (EJSO) 43:3, pages 581-593.
Crossref
Crossref
Ling Ling, Si Kee Tan, Ting Hwee Goh, Edwin Cheung, Victor Nurcombe, Andre J. van Wijnen & Simon M. Cool. (2015) Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy. Molecular Cancer 14:1.
Crossref
Crossref
Juan Li, Zhaolong Wei, Hongyu Li, Qi Dang, Zongpu Zhang, Linlin Wang, Wei Gao, Pei Zhang, Dong Yang, Jie Liu, Yuping Sun & Wei Gao. (2015) Clinicopathological significance of fibroblast growth factor 1 in non–small cell lung cancer. Human Pathology 46:12, pages 1821-1828.
Crossref
Crossref
Sandra Liekens, Sam Noppen, Sofie Gijsbers, Rebecca Sienaert, Roberto Ronca, Chiara Tobia & Marco Presta. (2014) The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget 6:7, pages 4633-4648.
Crossref
Crossref
Roberta Lelis Dutra, Marcelo dos Santos, Suzanny Oliveira Mendes, Gabriela Tonini Peterle, Iúri Drumond Louro & Adriana Madeira Álvares da Silva Conforti. 2015. Biomarkers in Cancer. Biomarkers in Cancer
809
826
.
Sumati Bhatia & Rainer Haag. 2015. Targeted Drug Delivery : Concepts and Design. Targeted Drug Delivery : Concepts and Design
543
569
.
Yi Hu, Huiru Lu, Jinchao Zhang, Jun Chen, Zhifang Chai & Jingxin Zhang. (2014) Essential role of AKT in tumor cells addicted to FGFR. Anti-Cancer Drugs 25:2, pages 183-188.
Crossref
Crossref
Delira Robbins & Taosheng Chen. (2014) Tissue-specific regulation of pregnane X receptor in cancer development and therapy. Cell & Bioscience 4:1, pages 17.
Crossref
Crossref
Roberta Lelis Dutra, Marcelo dos Santos, Suzanny Oliveira Mendes, Gabriela Tonini Peterle, Iúri Drumond Louro & Adriana Madeira Álvares da Silva Conforti. 2014. Biomarkers in Cancer. Biomarkers in Cancer
1
15
.
Roberto Ronca, Emanuela Di Salle, Arianna Giacomini, Daria Leali, Patrizia Alessi, Daniela Coltrini, Cosetta Ravelli, Sara Matarazzo, Domenico Ribatti, William Vermi & Marco Presta. (2013) Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells. Molecular Cancer Therapeutics 12:12, pages 2760-2771.
Crossref
Crossref
Atish Patel, Amit K. Tiwari, Eduardo E. Chufan, Kamlesh Sodani, Nagaraju Anreddy, Satyakam Singh, Suresh V. Ambudkar, Ralph Stephani & Zhe-Sheng Chen. (2013) PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology 72:1, pages 189-199.
Crossref
Crossref
V Chell, K Balmanno, A S Little, M Wilson, S Andrews, L Blockley, M Hampson, P R Gavine & S J Cook. (2012) Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 32:25, pages 3059-3070.
Crossref
Crossref
Roberta Lelis Dutra, Marcos Brasilino de Carvalho, Marcelo dos Santos, Ana Maria da Cunha Mercante, Diana Gazito, Rafael de Cicco, GENCAPO Group, Eloiza Helena Tajara, Iúri Drumond Louro & Adriana Madeira Álvares da Silva. (2012) FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx. PLoS ONE 7:11, pages e50747.
Crossref
Crossref
Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Li, Xue-Qian Gong, Sean Buchanan, James R. Henry, James J. Starling & Sheng-Bin Peng. (2012) Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma. Journal of Biological Chemistry 287:33, pages 28087-28098.
Crossref
Crossref
Larissa Sweeny, Zhiyong Liu, William Lancaster, Justin Hart, Yolanda E. Hartman & Eben L. Rosenthal. (2012) Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor. The Laryngoscope 122:7, pages 1539-1544.
Crossref
Crossref
Dorothy M. French, Benjamin C. Lin, Manping Wang, Camellia Adams, Theresa Shek, Kathy Hötzel, Brad Bolon, Ronald Ferrando, Craig Blackmore, Kurt Schroeder, Luis A. Rodriguez, Maria Hristopoulos, Rayna Venook, Avi Ashkenazi & Luc R. Desnoyers. (2012) Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models. PLoS ONE 7:5, pages e36713.
Crossref
Crossref
Thomas Metzner, Alexandra Bedeir, Gerlinde Held, Barbara Peter-Vörösmarty, Sara Ghassemi, Christine Heinzle, Sabine Spiegl-Kreinecker, Brigitte Marian, Klaus Holzmann, Bettina Grasl-Kraupp, Christine Pirker, Michael Micksche, Walter Berger, Petra Heffeter & Michael Grusch. (2011) Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. Journal of Investigative Dermatology 131:10, pages 2087-2095.
Crossref
Crossref
Zhiyong Liu, Yolanda E. Hartman, Jason M. Warram, Joseph A. Knowles, Larissa Sweeny, Tong Zhou & Eben L. Rosenthal. (2011) Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells. Molecular Cancer Research 9:8, pages 1008-1017.
Crossref
Crossref
Roy M. Bremnes, Tom Dønnem, Samer Al-Saad, Khalid Al-Shibli, Sigve Andersen, Rafael Sirera, Carlos Camps, Inigo Marinez & Lill-Tove Busund. (2011) The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, pages 209-217.
Crossref
Crossref
Israel S. Fernández, Pedro Cuevas, Javier Angulo, Pilar López-Navajas, Ángeles Canales-Mayordomo, Rocío González-Corrochano, Rosa M. Lozano, Serafín Valverde, Jesús Jiménez-Barbero, Antonio Romero & Guillermo Giménez-Gallego. (2010) Gentisic Acid, a Compound Associated with Plant Defense and a Metabolite of Aspirin, Heads a New Class of in Vivo Fibroblast Growth Factor Inhibitors. Journal of Biological Chemistry 285:15, pages 11714-11729.
Crossref
Crossref
Nina Seitzer, Thomas Mayr, Sylvia Streit & Axel Ullrich. (2010) A Single Nucleotide Change in the Mouse Genome Accelerates Breast Cancer Progression. Cancer Research 70:2, pages 802-812.
Crossref
Crossref
Victoria Knights & Simon J. Cook. (2010) De-regulated FGF receptors as therapeutic targets in cancer. Pharmacology & Therapeutics 125:1, pages 105-117.
Crossref
Crossref
Thommey P. Thomas, Rameshwer Shukla, Alina Kotlyar, Jola Kukowska-Latallo & James R. BakerJr.Jr.. (2010) Dendrimer-based tumor cell targeting of fibroblast growth factor-1. Bioorganic & Medicinal Chemistry Letters 20:2, pages 700-703.
Crossref
Crossref
Mark A. Socinski. (2009) Fibroblastic Growth Factor Pathway. Journal of Thoracic Oncology 4:11, pages S1066-S1067.
Crossref
Crossref
Daniele Fancelli & Jürgen Moll. 2009. Kinase Inhibitor Drugs. Kinase Inhibitor Drugs
281
307
.
Hendrik Fischer, Ninon Taylor, Sigrid Allerstorfer, Michael Grusch, Gudrun Sonvilla, Klaus Holzmann, Ulrike Setinek, Leonilla Elbling, Heidelinde Cantonati, Bettina Grasl-Kraupp, Christine Gauglhofer, Brigitte Marian, Michael Micksche & Walter Berger. (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Molecular Cancer Therapeutics 7:10, pages 3408-3419.
Crossref
Crossref
Rama Pai, Debra Dunlap, Jing Qing, Iman Mohtashemi, Kathy Hotzel & Dorothy M. French. (2008) Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating β-Catenin Signaling. Cancer Research 68:13, pages 5086-5095.
Crossref
Crossref
Noriko Gotoh. (2008) Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Science 99:7, pages 1319-1325.
Crossref
Crossref
L R Desnoyers, R Pai, R E Ferrando, K Hötzel, T Le, J Ross, R Carano, A D'Souza, J Qing, I Mohtashemi, A Ashkenazi & D M French. (2007) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27:1, pages 85-97.
Crossref
Crossref
Jan-Michel Otte, Martin Schwenger, Gabriele Brunke, Frank Schmitz, Claudia Otte, Karlheinz Kiehne, Sievert Kloehn, Heiner Mönig, Wolfgang E. Schmidt & Karl-Heinz Herzig. (2007) Differential regulated expression of keratinocyte growth factor and its receptor in experimental and human liver fibrosis. Regulatory Peptides 144:1-3, pages 82-90.
Crossref
Crossref
A.A. Mortlock & A.J. Barker. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
183
220
.
Huajie ZhangShumin ZhangHui ZhuangFengmin Lu. (2006) Cytotoxicity of a Novel Fibroblast Growth Factor Receptor Targeted Immunotoxin on a Human Ovarian Teratocarcinoma Cell Line. Cancer Biotherapy and Radiopharmaceuticals 21:4, pages 321-332.
Crossref
Crossref
Yongde Luo, Sheng Ye, Mikio Kan & Wallace L. McKeehan. (2006) Control of Fibroblast Growth Factor (FGF) 7- and FGF1-induced Mitogenesis and Downstream Signaling by Distinct Heparin Octasaccharide Motifs. Journal of Biological Chemistry 281:30, pages 21052-21061.
Crossref
Crossref
Christopher J. Robinson, Nicholas J. Harmer, Sarah J. Goodger, Tom L. Blundell & John T. Gallagher. (2005) Cooperative Dimerization of Fibroblast Growth Factor 1 (FGF1) upon a Single Heparin Saccharide May Drive the Formation of 2:2:1 FGF1·FGFR2c·Heparin Ternary Complexes. Journal of Biological Chemistry 280:51, pages 42274-42282.
Crossref
Crossref
Sylvia Streit, Johannes Bange, Alexander Fichtner, Stephan Ihrler, Wolfgang Issing & Axel Ullrich. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. International Journal of Cancer 111:2, pages 213-217.
Crossref
Crossref
Robert J. Linhardt & Toshihiko Toida. (2004) Role of Glycosaminoglycans in Cellular Communication. Accounts of Chemical Research 37:7, pages 431-438.
Crossref
Crossref
Nobuyuki Itoh. 2004. Encyclopedia of Endocrine Diseases. Encyclopedia of Endocrine Diseases
67
71
.
T.S. Udayakumar, Raymond B. Nagle & G. Tim Bowden. (2003) Fibroblast growth factor‐1 transcriptionally induces membrane type‐1 matrix metalloproteinase expression in prostate carcinoma cell line. The Prostate 58:1, pages 66-75.
Crossref
Crossref
Yuki Morimoto, Toshifumi Ozaki, Mamoru Ouchida, Norifumi Umehara, Norihide Ohata, Aki Yoshida, Kenji Shimizu & Hajime Inoue. (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98:10, pages 2245-2250.
Crossref
Crossref